Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06837480 · ClinicalTrials.gov registry record · NA

Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema

A NA study of Head and Neck Cancer and Lymphedema of the Head and Neck, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
2
Study locations

NCT06837480 is a NA study of Head and Neck Cancer and Lymphedema of the Head and Neck that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 150 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (42% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06837480, a NA study of Head and Neck Cancer and Lymphedema of the Head and Neck, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
2
Study locations

Study Summary

The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.

Interventions

  • DEVICE LTU-904 Portable Laser Therapy Unit (active laser device)
  • DEVICE LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)

Study Locations (2)

Pennsylvania

  • University of Pennsylvania Abramson Cancer Center - Philadelphia

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-01-15
Est. Completion 2029-11-30
Phase NA

What the Registry Record Tells You About NCT06837480

The ClinicalTrials.gov registry entry for NCT06837480 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (42% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which LTU-904 Portable Laser Therapy Unit (active laser device) is the first listed.

NCT06837480 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06837480 about?

NCT06837480 is a clinical study titled "Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema". The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for th...

What is the current status of trial NCT06837480?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-01-15. Estimated completion is 2029-11-30.

What conditions does trial NCT06837480 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Lymphedema of the Head and Neck.

What interventions are being tested in trial NCT06837480?

The interventions under investigation include: LTU-904 Portable Laser Therapy Unit (active laser device) (DEVICE), LTU-904 Portable Laser Therapy Unit (sham/inactive laser device) (DEVICE).

Who is sponsoring clinical trial NCT06837480?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06837480 being conducted?

This trial has 2 study locations across Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.